Recursion Pharmaceuticals, Inc. (RXRX)
Automate Your Wheel Strategy on RXRX
With Tiblio's Option Bot, you can configure your own wheel strategy including RXRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RXRX
- Rev/Share 0.1484
- Book/Share 2.3188
- PB 2.2253
- Debt/Equity 0.0995
- CurrentRatio 4.1142
- ROIC -0.4845
- MktCap 2062230120.0
- FreeCF/Share -0.9883
- PFCF -5.1808
- PE -3.6169
- Debt/Assets 0.0712
- DivYield 0
- ROE -0.7468
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.03, representing a -1.57% change from its previous close.
Read More
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Read More
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Read More
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Read More
Why Recursion Pharmaceuticals Stock Is Plummeting Today
Published: May 06, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Recursion Pharmaceuticals (RXRX -11.15%) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m.
Read More
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Read More
Recursion to Participate in Upcoming Investor Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.
Read More
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Published: May 05, 2025 by: The Motley Fool
Sentiment: Negative
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading.
Read More
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Officer and Chief Commercial Officer Ben Taylor - Chief Financial Officer Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning.
Read More
3 Monster Stocks to Hold for the Next 10 Years
Published: April 23, 2025 by: The Motley Fool
Sentiment: Positive
Got a little money and a lot of time? Say, 10 years or more?
Read More
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Published: April 18, 2025 by: The Motley Fool
Sentiment: Neutral
Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same.
Read More
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Published: April 11, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Recursion Pharmaceuticals (RXRX 17.52%) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.
Read More
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Read More
Why Recursion Pharmaceuticals Stock Is Sinking Today
Published: March 10, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Recursion Pharmaceuticals (RXRX -5.54%) were sinking 8.2% lower as of 10:57 a.m. ET on Monday.
Read More
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Published: March 03, 2025 by: Benzinga
Sentiment: Positive
Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.
Read More
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.
Read More
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.
Read More
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT.
Read More
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
Published: February 21, 2025 by: MarketBeat
Sentiment: Neutral
Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals.
Read More
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Read More
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Read More
About Recursion Pharmaceuticals, Inc. (RXRX)
- IPO Date 2021-04-16
- Website https://www.recursion.com
- Industry Biotechnology
- CEO Christopher C. Gibson
- Employees 800